DIABETES DEVICES AND DRUGS MARKET ANALYSIS

Diabetes Devices and Drugs Market, By Category (Diagnosis and Monitoring (Blood Glucose Monitoring Devices, Software Programs for Diabetes Monitoring, Artificial Pancreas, Other Testing Devices), Therapeutics (Insulin, Insulin Delivery, Oral Hypoglycemic Agents, Cell Therapies)), By Disease Type (Type 2 Diabetes, Type 1 Diabetes), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Jun 2023
Code : CMI3857
Pages :210
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Global Diabetes Devices And Drugs Market- Regional Analysis

North America is expected to dominate the global diabetes devices and drugs market over the forecast period with an estimated market share of 38.7% for the year 2023. This market dominance can be attributed to the high concentration of market leaders in the region. Key players like Abbott Laboratories, DexCom, Inc., Eli Lilly and Company, etc. have contributed significantly to the North America diabetes devices and drugs market growth. For instance, in November 2022, Eli Lilly and Company announced the plans for the launch of its Tempo Personalized Diabetes Management Platform in the U.S. The new platform is designed with an aim to assist both adult patients and clinicians make informed decisions backed by data for the management of type 1 or type 2 diabetes.

Global Diabetes Devices And Drugs Market: Key Players

Major players operating in the global diabetes devices and drugs market include Abbott Laboratories, Bristol-Myers Squibb, DexCom, Inc., Eli Lilly and Company, Companion Medical, GlaxoSmithKline plc, Glenmark Pharmaceuticals, Johnson & Johnson, Lupin Ltd., F. Hoffmann-La Roche AG, DreaMed Diabetes, Hua Medicine and Sanofi.